The National Institute for Health and Care Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Selective internal radiation therapy for primary cholangiocarcinoma.
The committee agreed that two pieces of guidance would be produced following consideration of the overview for SIRT for primary hepatocellular carcinoma and primary cholangiocarcinoma. Please see IP1038 Selective internal radiation therapy for primary liver cancer
Hepatocellular carcinoma is a type of primary liver cancer (a cancer that begins in the liver). Cholangiocarcinoma, or bile duct cancer, is a rare type of primary liver cancer. The bile ducts (tubes) carry bile from the liver to the small bowel. Bile helps digestion by breaking down fat in food.
Selective internal radiation therapy (known as SIRT) aims to kill cancer cells, causing as little damage to the surrounding tissues as possible. Tiny radioactive ‘beads’ are injected into branches of the artery that supplies blood to the liver. The beads then become trapped in the small blood vessels supplying the cancer, releasing radiation directly into the cancer cells and killing them.
J12.3 Selective internal radiotherapy with microspheres to lesion of liver
X65.3 Delivery of a fraction of interstitial radiotherapy
Y36.4 Introduction of non-removable radioactive substance into organ for brachytherapy NOC
Y53.4 Approach to organ under fluoroscopic control